Deucravacitinib, a tyrosine kinase 2 pseudokinase inhibitor, protects human EndoC-βH1 β-cells against proinflammatory insults

Overview of attention for article published in Frontiers in immunology, October 2023

Altmetric Badge

About this Attention Score

Good Attention Score compared to outputs of the same age (67th percentile)
High Attention Score compared to outputs of the same age and source (82nd percentile)

Mentioned by

twitter: 7 X users

reddit: 1 Redditor

Readers on

mendeley: 13 Mendeley

Summary X Reddit

So far, Altmetric has seen 9 X posts from 7 X users, with an upper bound of 36,332 followers.

RT @isletbiologylab: 📢 Our latest article, "Deucravacitinib, a tyrosine kinase 2 pseudokinase inhibitor, protects human EndoC-βH1 β-cells a…

21 Oct 2023

Reply Repost Favourite

📢 Our latest article, "Deucravacitinib, a tyrosine kinase 2 pseudokinase inhibitor, protects human EndoC-βH1 β-cells against proinflammatory insults", which was published on @FrontImmunol, is now available also on PubMed. #ICYMI https://t.co/cUMGdBe9rs

21 Oct 2023

Reply Repost Favourite

RT @isletbiologylab: We're extremely excited to share our most recent publication: "Deucravacitinib, a tyrosine kinase 2 pseudokinase inhib…

10 Oct 2023

Reply Repost Favourite

RT @isletbiologylab: We're extremely excited to share our most recent publication: "Deucravacitinib, a tyrosine kinase 2 pseudokinase inhib…

10 Oct 2023

Reply Repost Favourite

This page shows the most recent X posts that mention this research output.

Click here to find out how to access more activity, including 5 additional X posts.